Halo Collective Inc.

Halo Collective Inc. operates as a cannabis cultivation, manufacturing, and distribution company that grows, extracts, and processes cannabis flower, oils, and concentrates in the United States. It also offers edible products, including cannabis-infused gummies and a syrup-based drink in California and Oregon. In addition, the company markets branded and private label products. It sells its cannabis products principally to dispensaries under Hush, Mojave, and Exhale brands. The company serves licensed retailers and wholesalers. It has a strategic partnership with High Tide Inc; and with OG DNA Genetics Inc to develop genetics in Oregon. The company was formerly known as Halo Labs Inc. and changed its name to Halo Collective Inc. in January 2021. Halo Collective Inc. was founded in 2016 and is headquartered in Toronto, Canada.

Halo Collective Inc. trades as HCANF on OTC. The company is classified in Healthcare / Drug Manufacturers - Specialty & Generic and reports in USD.

The current profile places the business in Drug Manufacturers - Specialty & Generic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $24.54M of revenue and -$83.87M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Halo Collective Inc. can be compared against peers such as Aeolus Pharmaceuticals, Inc., CannTrust Holdings Inc., DrazCanna, Inc., Founders Bay Holdings, Lowell Farms Inc., MPX International Corporation.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $15,081, beta of 4.18, and return on equity of -257.4%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

HCANF currently shows total debt of $17.60M and beta of 4.18. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.haloco.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.